Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$12.21 USD
+0.38 (3.21%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $12.18 -0.03 (-0.25%) 7:50 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARCT 12.21 +0.38(3.21%)
Will ARCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Other News for ARCT
U.S. to phase out funding for mRNA vaccine development
Catherine Wood Reduces Stake in Arcturus Therapeutics Holdings Inc
ARCT Crosses Above Key Moving Average Level
Arcturus Therapeutics (ARCT) Maintains Sector Outperform; Price Target Raised | ARCT Stock News
Arcturus Therapeutics price target raised by $3 at Scotiabank, here's why